Claroid Pharmaceuticals Limited

rhp filedRefreshing

Source: SEBI

DRHP30 Sept 2026completed
RHP7 Oct 2026completed
Price band—not yet reached
Opens—not yet reached
Closes—not yet reached
Allotment—not yet reached
Listing—not yet reached

Issue price

—

Issue size

—

Fresh issue

—

Offer for sale

—

What the company does

Business model: Claroid Pharmaceuticals Limited is a pharmaceutical formulations manufacturing company focused on developing and exporting generic pharmaceutical products, particularly to semi-regulated international markets in Africa.
Revenue drivers: The company derives a substantial portion of its revenue from exports to Nigeria.
products: The company has developed 129 pharmaceutical formulations across various therapeutic segments.
Customers & concentration: The company is significantly dependent on its top ten customers, which contributed ₹10,424.69 Lakh, ₹6,917.00 Lakh, and ₹5,075.02 Lakh, representing 62.80%, 69.83%, and 81.38% of total sales for Fiscal 2026, 2025, and 2024, respectively.
geography: The company operates a manufacturing facility in Ahmedabad, Gujarat.
Industry structure: The Indian pharmaceutical industry is one of the largest and fastest-growing globally, recognized as the 3rd largest by volume and 11th largest by value.
Competitive position: The company has a distributor network of over 30 distributors across Africa.
Stated strengths: The company maintains strict quality control and assurance protocols throughout its operations.
Stated strategy: The company is focused on export of pharmaceutical products to semi-regulated international markets.

Key performance indicators

As disclosed by the issuer.

KPI	Value	Period	Pages
Revenue from Operations	16,971.53	Fiscal 2026	—
EBITDA	4,093.64	Fiscal 2026	—
Profit after tax	2,270.44	Fiscal 2026	—
Return on Equity	68.73%	Fiscal 2026	—

Context

What the company does

Claroid Pharmaceuticals Limited is engaged in the manufacturing and export of generic pharmaceutical products, primarily targeting semi-regulated markets in Africa. The company operates a manufacturing facility in Ahmedabad, Gujarat, with a focus on quality and compliance with regulatory standards.

Industry opportunity

The Indian pharmaceutical industry is one of the largest globally, recognized for its significant contribution to the supply of generic medicines. With a projected market growth rate of approximately 8.9% for FY 2026, Claroid Pharmaceuticals is positioned to capitalize on this expanding market.

KPI

Value

Period

Pages

Revenue from Operations

16,971.53

Fiscal 2026

—

EBITDA

4,093.64

Fiscal 2026

—

Profit after tax

2,270.44

Fiscal 2026

—

Return on Equity

68.73%

Fiscal 2026

—